青蒿琥酯治疗小儿脑型疟疾48例

目的探讨青蒿琥酯治疗小儿脑型疟疾的疗效。方法脑型疟疾患儿89例，随机分成治疗组（48例）和对照组（41例）；治疗组给予青蒿琥酯，对照组给予奎宁，观察7d后的疗效。结果7d治愈率治疗组为91．67％，对照组为85．37％，差异无统计学意义（P〉0．05）；两组的退热时间分别为（26．1±10．2）h和（39．5±11．6）h，昏迷苏醒时间分别为（36．2±10．1）h和（59．7±12．5）h，差异均有统计学意义（P〈0．01）。对照组的副作用相对较大。结论青蒿琥酯治疗脑型疟疾疗效好而迅速，副作用少，可以作为首选药。

Efficacy of Artesunate in the Treatment of Cerebral Malaria

Objective To evaluate the efficacy of artesunate in the treatment of children cerebral malaria. Methods Eighty-nine children with cerebral malaria were randomly divided into 2 groups. Patients of the treatment group （n=48） were given with artesunate. Patients of the control group （n=41） were given with quinimax. The effect was evaluated 7 days after the administration. Results Compare with the control group （85.37.%）, the curative rate of artesunate in the treatment group was 91.67% （P〉 0.05）. The abatement time of fever in the treatment and control group was （26.1 ± 10.2） h and （39.5 ± 11.6） h, respectively. The revival time after coma was （36.2±10.1） h in the treatment group and （59.7±12.5） h in the control group. The differences of the abatement time and revival time in these two group of patients were highly significant （P〈0.01）. The side effects of artesunate were also apparent in the control group. Conclusion Artesunate is more effective than quinine in the treatment of cerebral malaria. It may be used as the first line medicine.